Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
自閉症に関連する過敏性を有する小児患者の長期維持療法におけるアリピプラゾールの安全性と有効性
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Alabama
-
Dothan、Alabama、アメリカ、36303
- Harmonex Neuroscience Research, Inc
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Southwest Autism Research And Resource Center
-
-
California
-
Costa Mesa、California、アメリカ、92626
- Clinical Innovations, Inc.
-
Glendale、California、アメリカ、91206
- Behavioral Research Specialists, Llc
-
Palo Alto、California、アメリカ、94306
- Abbey Neuropsychology Clinic
-
San Francisco、California、アメリカ、94143
- Ucsf - Lppi
-
Stanford、California、アメリカ、94305
- Stanford University School Of Medicine
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children'S National Medical Center
-
-
Florida
-
Gainesville、Florida、アメリカ、32607
- Sarkis Clinical Trials
-
Hialeah、Florida、アメリカ、33012
- Palm Springs Research Institute
-
Maitland、Florida、アメリカ、32751
- Florida Clinical Research Center, Llc
-
Miami、Florida、アメリカ、33155
- Miami Children'S Hospital
-
Tampa、Florida、アメリカ、33613
- University Of South Florida
-
-
Georgia
-
Smyrna、Georgia、アメリカ、30080
- Institute For Behavioral Medicine, Llc
-
-
Idaho
-
Coeur d'Alene、Idaho、アメリカ、83814
- Kootenai Behavioral Health Center
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- Kosair Charities Pediatric Clinical Research Unit
-
-
Louisiana
-
Shreveport、Louisiana、アメリカ、71103
- Lsu Health Sciences Center
-
-
Massachusetts
-
Newton、Massachusetts、アメリカ、02459
- Neurocare, Inc.
-
-
Michigan
-
Bloomfield Hills、Michigan、アメリカ、48302
- Neurobehavioral Medicine Group
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89128
- Center For Psychiatry And Behavioral Medicine, Inc
-
-
New Jersey
-
Gibbsboro、New Jersey、アメリカ、08026
- Clinical Research Center Of New Jersey
-
Toms River、New Jersey、アメリカ、08755
- Children'S Specialized Hosp
-
-
New York
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University School Of Medicine
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27517
- Unc Chapel Hill
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals Case Medical Center
-
Cleveland、Ohio、アメリカ、44104
- Cleveland Clinic
-
Columbus、Ohio、アメリカ、43210
- The Ohio State University Nisonger Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73116
- Cutting Edge Research Group
-
Oklahoma City、Oklahoma、アメリカ、73117
- Ou Physician'S Child Study Center
-
Tulsa、Oklahoma、アメリカ、74104
- Tulsa Clinical Research, Llc
-
-
Oregon
-
Gresham、Oregon、アメリカ、97030
- Cyn3rgy Research
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19124
- Drexel University College Of Medicine
-
Pittsburgh、Pennsylvania、アメリカ、15203
- Western Psychiatric Institute And Clinic
-
-
Tennessee
-
Kingsport、Tennessee、アメリカ、37660
- Holston Medical Group
-
-
Texas
-
DeSoto、Texas、アメリカ、75115
- Insite Clinical Research
-
-
Utah
-
Clinton、Utah、アメリカ、84015
- Ericksen Research And Development
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23510
- Childrens Specialty Gr., Pllc
-
Richmond、Virginia、アメリカ、23298
- Virginia Treatment Center For Children
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
- Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
- Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
- Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
- An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
- Mental age of at least 24 months
Key Exclusion Criteria:
- Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
- Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
- Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
- Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
- History of neuroleptic malignant syndrome
- At significant risk for suicide based on history or routine psychiatric status examination
- A seizure within the past year
- History of severe head trauma or stroke
- History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
- Weight lower than 15 kg
- Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
- History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
- Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
Tablets, oral, 0 mg, once daily, 16 weeks |
|
実験的:アリピプラゾール
|
Tablets, oral, 2-15 mg, once daily, 13-42 weeks
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Patients Relapsing by Week 16
時間枠:From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment. |
From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
時間枠:From Baseline (end of Phase 1) to Week 16 of Phase 2
|
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
時間枠:From Baseline (end of Phase 1) to Week 16 of Phase 2
|
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
時間枠:Up to 26 weeks
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. |
Up to 26 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
時間枠:Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. |
Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22-30. doi: 10.4088/jcp.13m08500.
- Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CN138-603
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。